Loading...
Market
How many patients will be enrolled in PBGENE-HBV trial by end of 2025?
2
Resolution / Starting Odds
Less than 50 • 25%
50 to 100 • 25%
101 to 200 • 25%
More than 200 • 25%
Clinical trial registries or official reports from Precision BioSciences
Story
Moldova Approves Precision BioSciences' PBGENE-HBV Gene Editing Study for Chronic Hepatitis B
Oct 24, 2024, 12:51 PM
Moldova has approved its first gene editing study for human trials targeting Hepatitis B virus (HBV). Precision BioSciences has received the necessary approval to initiate the PBGENE-HBV clinical trial, which aims to test the effectiveness of gene editing in removing persistent viral DNA in patients with chronic HBV. This marks a significant step in gene therapy, as it will be the first human trial using such technology to address this viral infection.
View original story
Similar markets
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
0-10 patients • 33%
11-20 patients • 33%
More than 20 patients • 33%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 100 patients • 25%
100 to 500 patients • 25%
501 to 1000 patients • 25%
More than 1000 patients • 25%
Less than 50,000 • 25%
50,000 to 75,000 • 25%
75,000 to 100,000 • 25%
More than 100,000 • 25%
Less than 50 • 25%
50-100 • 25%
101-200 • 25%
More than 200 • 25%
Less than 100 • 25%
100 to 200 • 25%
201 to 300 • 25%
More than 300 • 25%
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,000 to 15,000 • 25%
More than 15,000 • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%